Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

PURPOSE: Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined with the PD-L1 inhibitor durvalumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Charu, Saba, Nabil F., Algazi, Alain, Sukari, Ammar, Seiwert, Tanguy Y., Haigentz, Missak, Porosnicu, Mercedes, Bonomi, Marcelo, Boyer, Jean, Esser, Mark T., Cheng, Lily I., Agrawal, Sonia, Jennings, Emily C., Durham, Nicholas M., Fraser, Karl, Lissa, Delphine, Gong, Maozhen, Ceaicovscaia, Natalia, Gascó Hernández, Amaya, Kumar, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890138/
https://www.ncbi.nlm.nih.gov/pubmed/36455147
http://dx.doi.org/10.1158/1078-0432.CCR-22-1987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890138/
https://www.ncbi.nlm.nih.gov/pubmed/36455147
http://dx.doi.org/10.1158/1078-0432.CCR-22-1987

Ejemplares similares